0000899243-23-012119.txt : 20230503
0000899243-23-012119.hdr.sgml : 20230503
20230503173944
ACCESSION NUMBER: 0000899243-23-012119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230501
FILED AS OF DATE: 20230503
DATE AS OF CHANGE: 20230503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40908
FILM NUMBER: 23885586
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER NAME:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MiNK Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 212-994-8250
MAIL ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: AgenTus Therapeutics, Inc.
DATE OF NAME CHANGE: 20210112
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-01
0
0001840229
MiNK Therapeutics, Inc.
INKT
0001098972
AGENUS INC
3 FORBES ROAD
LEXINGTON
MA
02421
0
0
1
0
0
Common Stock
2023-05-01
4
J
0
4988273
0.00
D
21344685
D
On May 1, 2023, Agenus Inc. ("Agenus") paid its previously announced pro rata stock dividend (the "Dividend") consisting of an aggregate of 4,988,081 shares of common stock of MiNK Therapeutics, Inc. ("MiNK") held by Agenus (the "Dividend Shares") to record holders of Agenus's common stock as of April 17, 2023 (the "Record Date"). Agenus distributed 0.0146 of a share of MiNK's common stock for each share of Agenus's common stock outstanding as of the close of business on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of Agenus who were entitled to receive fractional shares of the Dividend Shares received cash (without interest) in lieu of such fractional shares and 192 MiNK shares owned by Agenus that represented the aggregate number of fractional shares that would have been distributed were retired.
/s/ Christine Klaskin, Vice President, Finance
2023-05-03